A colloquy between Sen. Orrin Hatch and HHS Secretary Nominee Tom Price offered a timely rebuttal to a strangely one-sided investigative piece on the Orphan Drug law by Kaiser Health News and NPR.
The Senate Health, Education, Labor & Pensions Committee hearing on the nomination of Tom Price as HHS Secretary demonstrated that Price is a master of the fine art of dodging difficult questions without dismissing them.
Price was of course asked about the big topics of the day – repealing the Affordable Care Act being the...
Madrigal Pharmaceuticals’ resmetirom could become the first approved treatment for non-cirrhotic metabolic dysfunction-associated steatohepatitis in the EU, if the European Medicines Agency issues a positive opinion for the drug later this week.
Center for Biologics Evaluation and Research Director Vinay Prasad said Commissioner Martin Makary wants to release previously inaccessible FDA documents, but previous commissioners have made the same pronouncements only to make little progress.
The Pediatric Advisory Committee will review postmarketing safety for three vaccines and the oncologic drugs panel will consider the return of GSK’s belantamab mafodotin. An FDA notice about a 30 July meeting on Capricor’s deramiocel for Duchenne muscular dystrophy was withdrawn.
